Healthcare Stocks

Four Questions for the Recovery

13 7月 2021
5 Minute Read

Disappointing returns for healthcare stocks through the market’s recovery from the pandemic have raised concerns about the sector. But there’s still plenty of promising growth potential to be found. These four questions can help investors identify areas of interest.

Since the pandemic began, many investors have paid close attention to the healthcare sector. Yet global healthcare stocks have trailed the broader market since the recovery from the COVID-19-related crash began in April 2020 and in the year to date (Display).

Healthcare Stocks Have Underperformed Through the COVID-19 Recovery
Two sets of bars show MSCI World Healthcare returns vs MSCI World, from April 2020 to May 2021 and year-to-date through May.

Past performance and current analysis does not guarantee future results.
As of May 28, 2021
Returns are shown in USD terms.
Source: Morningstar, MSCI and AllianceBernstein (AB)

Why the underperformance? First, the sector was affected by a rotation into more economically sensitive industries and out of more defensive industries such as healthcare as investors positioned for an economic reopening post COVID-19. Second, unprofitable small- and mid-cap biotech companies have sold off this year, following strong but volatile gains in 2020. Lastly, rising interest rates have suppressed gains for growth stocks in general—including healthcare—which tend to benefit from lower discount rates. But these trends don’t undermine the long-term appeal of innovative healthcare companies with strong business fundamentals, in our view. The following questions can help guide the way to attractive opportunities in the sector.

1. How has the development of COVID-19 vaccines changed the healthcare industry?

Historic efforts to develop COVID-19 vaccines have had two huge effects on the industry. First, the success of mRNA technology has added an important weapon to drugmakers’ arsenals. We’ve learned from the pandemic that this new technology can be scaled up quickly to deliver a highly efficacious vaccine. It won’t be successful wherever it is applied. But we can look forward to new mRNA-driven efforts to develop vaccines for influenza—which has similarities to COVID-19—and also potentially for malaria, for HIV and in oncology.

Second, drug development has accelerated. The urgency of COVID-19 vaccines triggered innovations to clinical trials that will be applied more broadly. For example, instead of having patients come into hospitals for tests, we believe that some clinical trials will be able to utilize new technologies to monitor trial subjects remotely, effectively decentralizing the clinical trial process. Regulators have also shown they can cut red tape and hasten processes. Time-to-market for drug development may improve from the current standard of seven to 10 years by about a year or two, in light of these two trends.

2. What do the Biden administration’s policies mean for the US healthcare market?

Since President Biden’s election, there’s been quite a bit of talk about what policies he might apply to the healthcare sector, particularly on drug pricing or health insurance. So far, there haven’t been signs of major healthcare initiatives. Even within the Democratic party, there’s formidable opposition to major drug pricing reform such as reference pricing, which would link US drug prices to what’s being charged in Europe, or allowing the government to negotiate drug prices. Efforts to waive patents on COVID-19 vaccines to help reduce costs for emerging markets are also stuck. This requires international consensus, and Germany has recently opposed proposals to waive patents. So overall, we don’t expect any extreme policy changes for the healthcare sector under the new administration, which reduces policy risk for investors.

3. Does an ESG focus identify unique risks or opportunities for healthcare companies?

Integrating environmental, social and governance (ESG) factors in an analysis of healthcare companies is becoming increasingly important for equity investors. Since healthcare is an industry that has a profound impact on society, there’s a growing focus on the value of care provided for patients and communities. We believe companies that improve the value of care delivered make a positive impact on the healthcare system, which positions them well for growth in an era of rising healthcare costs and increased government involvement.

The value of care can be improved by decreasing the cost of service, increasing the benefit to patients or both. Another way to measure value is to connect healthcare with social determinants of health, such as housing, age, and community and education, which can help reduce adverse outcomes. Engaging with companies to increase the value delivered to patients is an effective ESG framework for investing in the healthcare sector, in our view.

4. What are the latest trends in healthcare that deserve investor attention?

Diagnostics is an exciting segment of the industry. The pandemic taught us the hard way that a more sophisticated testing infrastructure could have helped prevent the spread of COVID-19. So, there will be increased efforts—particularly by governments—to develop preventative diagnostics capabilities. We’ll see significant investment in surveillance and tracking systems.

Efforts to bring medical care closer to the home are growing. The more you can keep people out of the hospital and intervene earlier, the better it is for the patient and for society. Technology will also be used more broadly, for example, to identify patients who are at risk of a bad outcome, which can help determine the sequence of care.

Data analytics, too, are becoming more commonplace to improve outcomes in innovative ways. For example, data analytics can help surgeons refine their skill set and understand where their technique could be better.

These trends are creating fertile ground for equity investors. But don’t be blinded by science; exciting drugs in development and new technologies on their own aren’t good guides to investing success, in our view. Focusing on business fundamentals—balance sheets, competitive advantages, cash flows and profitability—is the best way to find innovative healthcare companies that are well positioned to deliver long-term returns to equity investors in a rapidly evolving post-pandemic world.

The views expressed herein do not constitute research, investment advice or trade recommendations and do not necessarily represent the views of all AB portfolio-management teams and are subject to revision over time.

MSCI makes no express or implied warranties or representations, and shall have no liability whatsoever with respect to any MSCI data contained herein.
The MSCI data may not be further redistributed or used as a basis for other indices or any securities or financial products. This report is not approved, reviewed or produced by MSCI.

Investment involves risk. The information contained here reflects the views of AllianceBernstein L.P. or its affiliates and sources it believes are reliable as of the date of this publication. AllianceBernstein L.P. makes no representations or warranties concerning the accuracy of any data. There is no guarantee that any projection, forecast or opinion in this material will be realized. Past performance does not guarantee future results. The views expressed here may change at any time after the date of this publication. This article is for informational purposes only and does not constitute investment advice. AllianceBernstein L.P. does not provide tax, legal or accounting advice. It does not take an investor's personal investment objectives or financial situation into account; investors should discuss their individual circumstances with appropriate professionals before making any decisions. This information should not be construed as sales or marketing material or an offer of solicitation for the purchase or sale of, any financial instrument, product or service sponsored by AllianceBernstein or its affiliates. This presentation is issued by AllianceBernstein Hong Kong Limited (聯博香港有限公司) and has not been reviewed by the Securities and Futures Commission


About the Authors